Skip to main content

Table 1 Incidence of anogenital warts and precancerous lesions in young women (2011–2018), by vaccination status

From: HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis

 

Incidence % (95% confidence interval)

Age (years)

 

Total number of diagnoses

Overall

Not vaccinated

Partially vaccinated

Fully vaccinated

Anogenital warts

 

n

 

433 620

218 953

93 330

121 337

19

43 565

137

0·31 (0·26 – 0·37)

0·44 (0·35 – 0·53)

0·20 (0·09 – 0·31)

0·21 (0·15 – 0·28)

20

44 314

224

0·51 (0·44 – 0·57)

0·72 (0·61 – 0·84)

0·35 (0·21 – 0·49)

0·30 (0·22 – 0·38)

21

44 809

348

0·78 (0·70 – 0·86)

1·06 (0·92 – 1·19)

0·58 (0·40– 0·77)

0·49 (0·38 – 0·60)

22

43 107

453

1·05 (0·96 – 1·15)

1·46 (1·30 – 1·62)

0·75 (0·54 – 0·97)

0·62 (0·50 – 0·74)

23

40 984

512

1·25 (1·14 – 1·36)

1·90 (1·71 – 2·09)

0·68 (0·49 – 0·88)

0·61 (0·48 – 0·74)

24

40 873

587

1·44 (1·32 – 1·55)

2·14 (1·93 – 2·34)

0·75 (0·56 – 0·93)

0·81 (0·65 – 0·96)

25

42 586

709

1·67 (1·54 – 1·79)

2·51 (2·29 – 2·72)

0·84 (0·67 – 1·02)

0·87 (0·70 – 1·05)

26

43 692

711

1·63 (1·51 – 1·75)

2·34 (2·14 – 2·54)

0·82 (0·67 – 0·97)

1·02 (0·80 – 1·23)

27

44 062

788

1·79 (1·67 – 1·91)

2·54 (2·34 – 2·73)

0·84 (0·68 – 0·99)

1·04 (0·79 – 1·29)

28

45 628

823

1·80 (1·68 – 1·93)

2·31 (2·14 – 2·49)

0·91 (0·75 – 1·07)

1·04 (0·68 – 1·40)

24–28

216 841

3618

1·67 (1·62 – 1·72)

2·37 (2·28 – 2·46)

0·84 (0·77 – 0·91)

0·92 (0·83 – 1·01)

19–28

433 620

5292

1·22 (1·19 – 1·25)

1·78 (1·72 – 1·83)

0·72 (0·67 – 0·78)

0·60 (0·56 – 0·64)

Precancerous lesions

 

n

 

434 458

219 455

93 499

121 504

19

43 607

78

0·18 (0·14 – 0·22)

0·17 (0·11 – 0·23)

0·28 (0·15 – 0·40)

0·15 (0·09 – 0·21)

20

44 355

144

0·33 (0·27 – 0·38)

0·31 (0·23 – 0·38)

0·30 (0·17 – 0·43)

0·35 (0·27 – 0·44)

21

44 830

188

0·42 (0·36 – 0·48)

0·44 (0·35 – 0·52)

0·40 (0·25 – 0·56)

0·41 (0·31 – 0·50)

22

43 143

280

0·65 (0·57 – 0·73)

0·70 (0·59 – 0·81)

0·67 (0·47 – 0·87)

0·57 (0·45 – 0·69)

23

41 011

347

0·85 (0·76 – 0·94)

0·87 (0·74 – 1.00)

0·80 (0·59 – 1·01)

0·84 (0·69 – 0·99)

24

40 913

462

1·13 (1·03 – 1·23)

1·27 (1·11 – 1·43)

1·18 (0·95 – 1·41)

0·88 (0·71 – 1·04)

25

42 663

547

1·28 (1·18 – 1·39)

1·46 (1·30 – 1·63)

1·27 (1·06 – 1·48)

0·94 (0·76 – 1·13)

26

43 811

701

1·60 (1·48 – 1·72)

1·87 (1·69 – 2·04)

1·43 (1·23 – 1·64)

1·15 (0·92 – 1·38)

27

44 249

761

1·72 (1·60 – 1·84)

2·01 (1·83 – 2·18)

1·46 (1·26 – 1·66)

1·19 (0·93 – 1·46)

28

45 876

877

1·91 (1·79 – 2·04)

2·15 (1·98 – 2·32)

1·55 (1·34 – 1·75)

1·33 (0·93 – 1·73)

24–28

217 512

3348

1·54 (1·49 – 1·59)

1·79 (1·72 – 1·87)

1·40 (1·31 – 1·50)

1·03 (0·93 – 1·13)

19–28

434 458

4385

1·01 (0·98 – 1·04)

1·18 (1·14 – 1·23)

1·08 (1·01 – 1·15)

0·65 (0·60 – 0·69)

  1. Analysis population: Young women aged 19 to 28 years (birth year 1990 to 1999); Abbreviations: n: number of females in each vaccination category and age group; %: percent. Definitions: Partially vaccinated: one dose (age nine to 14), one or two doses (from age 15), or when the interval between the first and last dose was shorter than six months; Fully vaccinated: two doses at age nine to 14 years or three doses from age 15